Clinical Trials
10 trialsNCT05464719 2026-05-20
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05453396 2026-05-11
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
University of Washington
Phase 2 Recruiting
NCT05672251 2026-05-11
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT04998669 2026-03-23
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
University of Miami
Phase 2 Recruiting
NCT04970901 2026-03-13
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
ADC Therapeutics S.A.
Phase 1 Recruiting
NCT05991388 2026-02-20
Glo-BNHL
University of Birmingham
Phase 2/3 Recruiting
NCT05249959 2026-01-05
FIL_COLUMN
Fondazione Italiana Linfomi - ETS
Phase 2 Recruiting
NCT05296070 2025-09-30
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
University of Miami
Phase 2 Recruiting
NCT06977711 2025-08-05
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
The University of Texas Health Science Center at San Antonio
Phase 1 Recruiting
NCT05660395 2025-07-16
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
ADC Therapeutics S.A.
Phase 1 Recruiting